![Lisa Rojkjaer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lisa Rojkjaer
Chief Tech/Sci/R&D Officer at
RIGEL PHARMACEUTICALS, INC.
Net worth: 1 M $ as of 31/05/2026
Profile
Lisa Rojkjaer currently works at Rigel Pharmaceuticals, Inc., as Chief Medical Officer & Executive Vice President from 2024.
Dr. Rojkjaer also formerly worked at Novartis Oncology, Inc., as Head-AML Global Clinical Program from 2013 to 2016, Sunesis Pharmaceuticals, Inc., as Chief Medical Officer, MorphoSys AG, as Vice President & Head-Clinical Development, Novo Nordisk, Inc., as Head-Clinical Development & Hematology, Molecular Partners AG, as Chief Medical Officer, Novartis Pharma AG, as Head-Global Clinical Program, Nordic Nanovector ASA, as Chief Medical Officer from 2016 to 2020, Viracta Therapeutics, Inc., as Chief Medical Officer from 2020 to 2023, Sangamo Therapeutics, Inc., as Chief Medical Officer, and Viracta Subsidiary, Inc., as Chief Medical Officer.
Dr. Rojkjaer received her doctorate degree from the University of Toronto.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/06/2026 | 34,003 ( 0.18% ) | 1 M $ | 31/05/2026 |
Lisa Rojkjaer active positions
| Companies | Position | Start |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 12/03/2024 |
Former positions of Lisa Rojkjaer
| Companies | Position | End |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 05/05/2023 |
| THOR MEDICAL | Chief Tech/Sci/R&D Officer | 01/04/2020 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | 01/11/2016 |
| SANGAMO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Chief Tech/Sci/R&D Officer | - |
Training of Lisa Rojkjaer
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
15
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
Rigel Pharmaceuticals, Inc.
 Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs | Health Technology |
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Develops biological medicines | Health Technology |
Molecular Partners AG
 Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Develops innovative anticancer therapeutics | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
- Stock Market
- Insiders
- Lisa Rojkjaer
